Kiromic's previous CFO, Tony Tontat, resigned on September 29, 2021, effective immediately.
Clark joined Kiromic in February 2020 and served as the company's Corporate Controller until September 2021, when he was promoted to vice president finance operations.
Before joining the company, Clark was a manager with The Siegfried Group, a national accounting services firm, from June 2018 to February 2020.
Prior to his employment with The Siegfried Group, Clark served as Senior Consultant - Office of the CFO Solutions for FTI Consulting, a global financial consulting firm, from January 2017 to May 2018. Prior to that, Clark was Senior Associate - Audit at KPMG US, a member of Big Four global accounting firm KPMG, from August 2011 to June 2015.
Kiromic BioPharma is an AI-driven, end-to-end CAR-T and gene therapy company, developing the first multi-indication allogeneic CAR-T cell therapy, that exploits the natural potency of Gamma Delta T-cells to target solid cancers.
Kiromic BioPharma is focused on discovering, developing, and commercializing novel immune-oncology applications through its product pipeline. The pipeline development is leveraged through the company's proprietary target discovery engine called "DIAMOND."
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer